DiscGenics, Inc.

DiscGenics, Inc. develops regenerative therapies for chronic back pain, focusing on their investigational product, IDCT, which targets lumbar disc degeneration using proprietary cell therapy technology. Founded in 2007 and headquartered in Salt Lake City, US, DiscGenics, Inc. specializes in innovative therapies for spinal health.

The company has raised a total of USD 50. 00 mn in funding through 4 deals, with the latest being a Series C round in August 2020 led by Ci:z Investment LLP, alongside participation from CareNet Group, Eagle Funding & Investment, Medical Incubator Japan, and Mitsubishi UFJ Capital. The CEO, Flagg Flanagan, has a history in healthcare entrepreneurship, having founded and led other ventures in the medical field. DiscGenics specializes in developing innovative regenerative therapies aimed at addressing chronic back pain, particularly through their core product, IDCT (rebonuputemcel).

This investigational product is an allogeneic, injectable cell therapy that uses proprietary Discogenic Cells to target mild to moderate adult lumbar disc degeneration. By focusing on the unique environment of degenerated spinal discs, DiscGenics aims to alleviate pain and restore functionality for patients suffering from degenerative diseases of the spine. The primary end users of IDCT are adults experiencing chronic back pain due to disc degeneration, with a focus on enhancing their quality of life. While specific geographical markets have not been detailed, the company aims to serve patients and healthcare providers in regions where there is a significant prevalence of degenerative spinal conditions.

DiscGenics operates within a healthcare framework that is centered on innovative therapies and clinical research. Revenue generation is primarily structured around partnerships with healthcare institutions and participation in clinical trials, where their flagship product, IDCT, is currently under investigation. The company’s transaction model involves direct collaborations with hospitals and clinics, allowing for the administration of their cell therapy to patients enrolled in clinical studies. As the product advances through regulatory pathways, potential revenue streams may include agreements with healthcare providers for the integration of IDCT into treatment protocols, contingent upon successful clinical outcomes and subsequent approvals.

Specific pricing structures or transaction details are not publicly disclosed, reflecting the proprietary nature of their operations within the specialized field of regenerative medicine. DiscGenics plans to utilize the USD 50. 00 mn raised in their Series C funding in August 2020 to advance the development of IDCT and other potential products. The company aims to expand its clinical trials and increase outreach to healthcare providers.

Specific geographical markets targeted for expansion have not been disclosed, but the funding will support initiatives to enhance availability of their therapies in regions with high incidences of degenerative spinal conditions.